Norway's sovereign fund logo reflecting divestment from Israeli stocks amid Gaza conflict - Global Banking & Finance Review
The image depicts the logo of Norway's Sovereign Fund, which plans to divest from Israeli companies due to the ongoing humanitarian crisis in Gaza. This decision reflects ethical investment practices and highlights the fund's significant influence in global finance.
Finance

Siemens Healthineers cuts 2026 outlook

Published by Global Banking & Finance Review

Posted on May 7, 2026

1 min read

· Last updated: May 7, 2026

Add as preferred source on Google

Siemens Healthineers Lowers 2026 Revenue Outlook Citing China and Inflation Issues

Siemens Healthineers Revises Financial Forecasts for 2026

Reduced Revenue Growth Expectations

May 7 (Reuters) - Siemens Healthineers on Thursday cut its full year outlook to forecast revenue growth of between 4.5% and 5.0% for the 2026 financial year due to weakness in China's diagnostics market and higher inflation during the quarter.

Previous Revenue and Earnings Forecasts

The company had previously forecast annual revenue growth between 5% and 6% and earnings per share range of 2.20 to 2.40 euros for 2026.

Updated Earnings Per Share Outlook

The German medical technology company also revised its outlook for earnings per share downwards to 2.20-2.30 euros. 

(Reporting by Simon Ferdinand Eibach; Editing by Nivedita Bhattacharjee)

Key Takeaways

  • Diagnostics in China slumped—Diagnostics revenue fell 6.5% in Q2 with margin collapsing to 0.9%, prompting reevaluation of outlook and strategic options for the unit (investing.com).
  • Imaging and Precision Therapy remain resilient—Imaging revenue rose 6.1% and Precision Therapy grew 4.7%, helping buffer broader performance (investing.com).
  • The revised EPS guidance lowered the upper bound from €2.40 to €2.30, while leaving the lower bound unchanged, reflecting cost headwinds and persistent macro pressures (uk.marketscreener.com).

References

Frequently Asked Questions

Why did Siemens Healthineers revise its 2026 outlook?
The company revised its outlook due to weakness in China's diagnostics market and higher inflation.
How does the new earnings per share guidance compare to previous estimates?
The revised earnings per share outlook for 2026 is 2.20-2.30 euros, down from the prior 2.20-2.40 euro range.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category